Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity

Journal of Virological Methods

Volumn 165, Issue 2, 2010, Pages 186-197

  Gali, Youssef ^a,b   Ariën, Kevin K ^a   Praet, Marleen ^c   Van den Bergh, Rafael ^d,e   Temmerman, Marleen ^f   Delezay, Olivier ^g   Vanham, Guido ^a,b,h  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f GHENT UNIVERSITY   (Belgium)

^g UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^h FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Dual chamber model; Epithelial toxicity; Female genital tract; HIV 1 transmission; Microbicides; Transmigration

Indexed keywords

INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ARTICLE; BIOLOGICAL MODEL; CELL ASSAY; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; EPITHELIUM; EPITHELIUM CELL; FEMALE GENITAL SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIAL ACTIVITY; NONHUMAN; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CELL CULTURE TECHNIQUES; CELL LINE; CERVIX UTERI; CHEMOKINE CCL2; CHEMOKINE CCL20; COCULTURE TECHNIQUES; ENDOMETRIUM; EPITHELIAL CELLS; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; NONOXYNOL; ORGAN SPECIFICITY; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; UTERUS; VAGINA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77951022974     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2010.01.018     Document Type: Article

References (57)

1. Adler K., Erickson T., Bobrow M. High sensitivity detection of HPV-16 in SiHa and CaSki cells utilizing FISH enhanced by TSA. Histochem. Cell Biol. 1997, 108:321-324.
2. Anderson D.J., Pudney J., Schust D.J. Caveats associated with the use of human cervical tissue for HIV and microbicide research. AIDS 2010, 24:1-4.
3. Baker C.C., Phelps W.C., Lindgren V., Braun M.J., Gonda M.A., Howley P.M. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 1987, 61:962-971.
4. Balda M.S., Matter K. Tight junctions. J. Cell Sci. 1998, 111(Pt 5):541-547.
5. Balda M.S., Whitney J.A., Flores C., Gonzalez S., Cereijido M., Matter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J. Cell Biol. 1996, 134:1031-1049.
6. Beer B.E., Doncel G.F., Krebs F.C., Shattock R.J., Fletcher P.S., Buckheit R.W., Watson K., Dezzutti C.S., Cummins J.E., Bromley E., Richardson-Harman N., Pallansch L.A., Lackman-Smith C., Osterling C., Mankowski M., Miller S.R., Catalone B.J., Welsh P.A., Howett M.K., Wigdahl B., Turpin J.A., Reichelderfer P. In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob. Agents Chemother. 2006, 50:713-723.
7. Behrens I., Kissel T. Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers?. Eur. J. Pharm. Sci. 2003, 19:433-442.
8. Beirnaert E., Willems B., Peeters M., Bouckaert A., Heyndrickx L., Zhong P., Vereecken K., Coppens S., Davis D., Ndumbe P., Janssens W., van der Groen G. Design and evaluation of an in-house HIV-1 (group M and O), SIVmnd and SIVcpz antigen capture assay. J. Virol. Methods 1998, 73:65-70.
9. Blocker M.E., Cohen M.S. Biologic approaches to the prevention of sexual transmission of human immunodeficiency virus. Infect. Dis. Clin. N. Am. 2000, 14:983-999.
10. Bobardt M.D., Chatterji U., Selvarajah S., Van der Schueren B., David G., Kahn B., Gallay P.A. Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J. Virol. 2007, 81:395-405.
11. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 1997, 3:42-47.
12. Carr M.W., Roth S.J., Luther E., Rose S.S., Springer T.A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:3652-3656.
13. Carreno M.P., Chomont N., Kazatchkine M.D., Irinopoulou T., Krief C., Mohamed A.S., Andreoletti L., Matta M., Belec L. Binding of LFA-1 (CD11a) to intercellular adhesion molecule 3 (ICAM-3; CD50) and ICAM-2 (CD102) triggers transmigration of human immunodeficiency virus type 1-infected monocytes through mucosal epithelial cells. J. Virol. 2002, 76:32-40.
14. Coombs R.W., Reichelderfer P.S., Landay A.L. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003, 17:455-480.
15. Cummins J.E., Guarner J., Flowers L., Guenthner P.C., Bartlett J., Morken T., Grohskopf L.A., Paxton L., Dezzutti C.S. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob. Agents Chemother. 2007, 51:1770-1779.
16. Cutler B., Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 2008, 8:685-697.
17. Dezzutti C.S., Guenthner P.C., Cummins J.E., Cabrera T., Marshall J.H., Dillberger A., Lal R.B. Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J. Infect. Dis. 2001, 183:1204-1213.
18. Dezzutti C.S., James V.N., Ramos A., Sullivan S.T., Siddig A., Bush T.J., Grohskopf L.A., Paxton L., Subbarao S., Hart C.E. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 2004, 48:3834-3844.
19. Di Fabio S., Giannini G., Lapenta C., Spada M., Binelli A., Germinario E., Sestili P., Belardelli F., Proietti E., Vella S. Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. AIDS 2001, 15:2231-2238.
20. Elias C.J., Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS 1996, 10(Suppl. 3):S43-S51.
21. Feldblum P.J., Adeiga A., Bakare R., Wevill S., Lendvay A., Obadaki F., Olayemi M.O., Wang L., Nanda K., Rountree W. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE 2008, 3:e1474.
22. Fichorova R.N., Bajpai M., Chandra N., Hsiu J.G., Spangler M., Ratnam V., Doncel G.F. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol. Reprod. 2004, 71:761-769.
23. Fichorova R.N., Rheinwald J.G., Anderson D.J. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol. Reprod. 1997, 57:847-855.
24. Fichorova R.N., Tucker L.D., Anderson D.J. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J. Infect. Dis. 2001, 184:418-428.
25. Fletcher P., Harman S., Azijn H., Armanasco N., Manlow P., Perumal D., de Bethune M.P., Nuttall J., Romano J., Shattock R. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 2009, 53:487-495.
26. Furuta Y., Eriksson K., Svennerholm B., Fredman P., Horal P., Jeansson S., Vahlne A., Holmgren J., Czerkinsky C. Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:12559-12563.
27. Greenhead P., Hayes P., Watts P.S., Laing K.G., Griffin G.E., Shattock R.J. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J. Virol. 2000, 74:5577-5586.
28. Guenthner P.C., Secor W.E., Dezzutti C.S. Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1. Infect. Immun. 2005, 73:4155-4160.
29. Halpern V., Ogunsola F., Obunge O., Wang C.-H., Onyejepu N., Oduyebo O., Taylor D., McNeil L., Mehta N., Umo-Otong J., Otusanya S., Crucitti T., Abdellati S. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS ONE 2008, 3:e3784.
30. Hillier S.L., Moench T., Shattock R., Black R., Reichelderfer P., Veronese F. In vitro and in vivo: the story of nonoxynol 9. J. Acquir. Immune Defic. Syndr. 2005, 39:1-8.
31. Hocini H., Becquart P., Bouhlal H., Adle-Biassette H., Kazatchkine M.D., Belec L. Secretory Leukocyte Protease Inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers. Clin. Diagn. Lab. Immunol. 2000, 7:515-518.
32. Khanna K.V., Whaley K.J., Zeitlin L., Moench T.R., Mehrazar K., Cone R.A., Liao Z., Hildreth J.E., Hoen T.E., Shultz L., Markham R.B. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Invest. 2002, 109:205-211.
33. Kleinman H.K., Graf J., Iwamoto Y., Kitten G.T., Ogle R.C., Sasaki M., Yamada Y., Martin G.R., Luckenbill-Edds L. Role of basement membranes in cell differentiation. Ann. N. Y. Acad. Sci. 1987, 513:134-145.
34. Krebs F.C., Miller S.R., Catalone B.J., Fichorova R., Anderson D., Malamud D., Howett M.K., Wigdahl B. Comparative in vitro sensitivities of human immune cell lines, vaginal and cervical epithelial cell lines, and primary cells to candidate microbicides nonoxynol 9, C31G, and sodium dodecyl sulfate. Antimicrob. Agents Chemother. 2002, 46:2292-2298.
35. Kuramoto H., Tamura S., Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am. J. Obstet. Gynecol. 1972, 114:1012-1019.
36. Lederman M.M., Offord R.E., Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 2006, 6:371-382.
37. Li Q., Estes J.D., Schlievert P.M., Duan L., Brosnahan A.J., Southern P.J., Reilly C.S., Peterson M.L., Schultz-Darken N., Brunner K.G., Nephew K.R., Pambuccian S., Lifson J.D., Carlis J.V., Haase A.T. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009, 458:1034-1038.
38. McNeely T.B., Shugars D.C., Rosendahl M., Tucker C., Eisenberg S.P., Wahl S.M. Inhibition of human immunodeficiency virus type 1 infectivity by Secretory Leukocyte Protease Inhibitor occurs prior to viral reverse transcription. Blood 1997, 90:1141-1149.
39. Mesquita P.M., Cheshenko N., Wilson S.S., Mhatre M., Guzman E., Fakioglu E., Keller M.J., Herold B.C. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J. Infect. Dis. 2009, 200:599-608.
40. Narimatsu R., Wolday D., Patterson B.K. IL-8 increases transmission of HIV type 1 in cervical explant tissue. AIDS Res. Hum. Retrovir. 2005, 21:228-233.
41. Poonia B., Wang X., Veazey R.S. Distribution of simian immunodeficiency virus target cells in vaginal tissues of normal rhesus macaques: implications for virus transmission. J. Reprod. Immunol. 2006, 72:74-84.
42. Pope M. Dendritic cells as a conduit to improve HIV vaccines. Curr. Mol. Med. 2003, 3:229-242.
43. Pudney J., Quayle A.J., Anderson D.J. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod. 2005, 73:1253-1263.
44. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
45. Reuter S., Delius H., Kahn T., Hofmann B., zur Hausen H., Schwarz E. Characterization of a novel human papillomavirus DNA in the cervical carcinoma cell line ME180. J. Virol. 1991, 65:5564-5568.
46. Saidi H., Nasreddine N., Jenabian M.A., Lecerf M., Schols D., Krief C., Balzarini J., Belec L. Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-d-mannose specific plant lectins: implication for microbicide development. J. Trans. Med. 2007, 5:28.
47. Shattock R.J., Moore J.P. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 2003, 1:25-34.
48. Shen R., Richter H.E., Clements R.H., Novak L., Huff K., Bimczok D., Sankaran-Walters S., Dandekar S., Clapham P.R., Smythies L.E., Smith P.D. Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:3258-3267.
49. Skoler-Karpoff S., Ramjee G., Ahmed K., Altini L., Plagianos M.G., Friedland B., Govender S., De Kock A., Cassim N., Palanee T., Dozier G., Maguire R., Lahteenmaki P. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1977-1987.
50. Sugaya M., Lore K., Koup R.A., Douek D.C., Blauvelt A. HIV-infected Langerhans cells preferentially transmit virus to proliferating autologous CD4+ memory T cells located within Langerhans cell-T cell clusters. J. Immunol. 2004, 172:2219-2224.
51. Tan X., Phillips D.M. Cell-mediated infection of cervix derived epithelial cells with primary isolates of human immunodeficiency virus. Arch. Virol. 1996, 141:1177-1189.
52. Terrazas-Aranda K., Van Herrewege Y., Hazuda D., Lewi P., Costi R., Di Santo R., Cara A., Vanham G. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob. Agents Chemother. 2008, 52:2544-2554.
53. UNAIDS, 2008. Report on the global AIDS epidemic 2008. http://www.unaids.org/.
54. Van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., Sirivongrangson P., Tshibaka L.M., Ettiègne-Traoré V., Uaheowitchai C., Karim S.S.A., Mâsse B., Perriëns J., Laga M. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. The Lancet 2002, 360:971-977.
55. Van Herrewege Y., Michiels J., Waeytens A., De Boeck G., Salden E., Heyndrickx L., van den Mooter G., de Bethune M.P., Andries K., Lewi P., Praet M., Vanham G. A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides. Antivir. Res. 2007, 74:111-124.
56. Wiedmann-Al-Ahmad M., Gutwald R., Lauer G., Hubner U., Schmelzeisen R. How to optimize seeding and culturing of human osteoblast-like cells on various biomaterials. Biomaterials 2002, 23:3319-3328.
57. Xu L.L., Warren M.K., Rose W.L., Gong W., Wang J.M. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J. Leukoc. Biol. 1996, 60:365-371.